NovaRx Corporation is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel, effective immunotherapies for the treatment of cancer.
Company was originally
founded in 1997 by Dr. Habib Fakhrai and Mr. Emmet O'Neal III to
the award-winning research of Dr. Fakhrai and associates at the
Our platform consists of allogeneic tumor cell vaccines in which the expression of TGF-β, a potent immunosuppressor, is downregulated, enabling the vaccine to induce strong immune responses that lead to increased survival. Lucanix®, a therapeutic vaccine for lung cancer, has shown clinical efficacy in multiple trials and is ready to launch a pivotal Phase 3 trial. Glionix, a therapeutic vaccine for glioma, is ready to start a Phase 2/3 trial. A universal tumor cell vaccine has been developed to treat most cancer indications.
Our lead product, Lucanix, was tested in an international, controlled Phase 3 trial for patients with advanced non-small cell lung cancer. It demonstrated a clear survival advantage in patients who had recently completed frontline chemotherapy.
We are also developing a pipeline of other oncology products that include biomarkers associated with clinical responses to immunotherapy and small cytotoxic molecules that preferentially target tumor stem cells.